Anticancer agents drive from Bacillus thuringiensis
Bioactive agents
DOI:
https://doi.org/10.33687/ricosbiol.02.01.0021Keywords:
Bacillus thuringiensis, cytotoxic, cytocidal activity, anticancer, tumericidalAbstract
Cancer is one of the most fatal diseases that rarely any cancer patient survives from it. Cancer affect different ages and sex causing great humanity losses reaches up to 100,000 patient / year according to the recent statistical analysis. It also, affects different tissues causing irreversible cytopathological changes result in highly undifferentiated cells that hard to be controlled or eradicated. The chemotherapy, radiotherapy and surgical interference still used in elimination of the disease since decades however both radiotherapy and chemotherapy did not prove acceptable success in the cancer treatment until now, unfortunately the surgical interference could not be more helpful as it did not overcome the malignancy metastasis which gets back wilder after surgical interference due to metastasis. So, it was sound good to use the biological anti-malignancy agents in eradication of cancer cells. Biological anticancer agents provide a confident success in cancer therapy which includes many microbial metabolites derived from the members of Family Bacillacae such as Bacillus thuringiensis, Bacillus polymixa and other members explored recently in the Saudi environment. For example in a previous studies recorded by us some serovars of Bacillus thuringiensis enzymatically activated parasporal inclusion proteins proved a potent anti-malignancy effect on acute lymphocyte leukemia, lung carcinoma, larynx carcinoma and uterine cervix carcinoma in vitro and a great result was recorded in vivo on the Ehirlch Acites Carcinoma. These biological anti-malignancy agents had a selective direct cytotoxic effect on cancer cells in addition to improving the immune status (immunomodulation) which helps in destruction of the cancer cells and dysfunction of their metastasis properties.Downloads
References
De Boer, E.C., De Jong, W.H., Steerenberg, P.A. et al., (1992). Inductino of urinary interleukin1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunoteherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother, 34: 306.
Dundas, S., Surphy, J., Soutar, R.L., Jones, G.A., Hutchinson, S.J. and Todd, W.T.A. (1999). Effectiveness of therapeutic plasma exchange in the 1996 Lanarkashire Escherichia coli O157: H7 outbreak. Lancet 354, 1327-1330.
Fichera, G. A. and Giese, G.,(1995). Non-immunologically-mediated cytotoxicityof Lactobacillus casei and its derivative paptidoglucan against tumour cell lines. Cancer Lett,85:93.
11-Hamilton-Miller, J.M. (2003). The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J. Antimicrob Agents 22, 360-366.
Hara, H., Watanabe, M., Masuno, T. et al., (1989). Studies on efficacious mechanism of LC9018 for malignant pleural effusion. Biotherapy, 3: 1607.
Hori, K., Ehrke, M.J., Mace, K. et al., (1987). Effect of recombinant human tumor necross factor on the induction of murine macrophage tumoricidal activity. Cancer Res., 47: 2793.
Jin, I.Z., Ho, Y.W., Ali, M.A. Abdullah, N. and Jalaludin, S. (1996). Effect of adherent Lactobacillus spp. in vitro adherence of salmonellae to the intestinal epithelial cells of chicken. J. Appl Microbiol 81, 201-206.
Karmarkar, M.G., Gershom, E.S.a nd Mehta, P.R. (2004). Enterococcal infections with special reference to phenotypic characterization & drug resisance. Indian J. Med Rs 119, 22-25.
Le, J., Prensky, W., Yip, Y.K. et al., (1983). Activation of human monocyte cytotoxicity by natural and recombinant immune interferon. J. Immunol., 131: 2821.
17-Lim, B. K., Mahendran, R., Lee, Y. K. and Bay, B. H.,(2002). Chemopreventive effect of Lactobacillus rhamnosus on growh of a subcutaneously implanted bladder cancer cell line in the mouse. JPn J Cancer Res,93:36.
Masuno, T., Kishimoto, S., Ogura, T. et al., (1991). A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer. Cancer, 68: 1495.
Matsuzaki, T. (1998). Immunomodulation by treatment with Lactobacillus casei strain Shiraota. Int J. Food Microbiol, 41: 133.
Matsuzaki, T., Yokokura, T. and Mutai, M. (1988) Antitumor effect of intrepleural administration of Lactobacillus casei in mice.Cancer Immunol Immunother,26:209.
Manjunath, N. and Raganathan, B. (1989). A cytotoxic substance produced by a wild culture of Lactobacillus casei D-34 against tumour cells. Indian J Exp Biol,27:141.
Naidu A.S., Bidlack W.R., Clemens, R.A. (1999). Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr., Jan. 39(1): 13-126.
O'Flaherty, S., R.P., Meaney, W., Fitzgerald, G.F., Elbreki, M.F. and Coffey, A. (2005) Potential of the Polyvalent anti-Staphylococcus bacteriophage K for cobtrol of antibiotic-resistant staphylococci from gospitals. Appl Environl Microbiol 71, 1836-1842.
Okawa, T. Niibe, H., Arai, T. et al., (1993). Effect of LC9018 combined with radiation therapy on carcinoma of the uterine cervix. A phase III, multicenter, randomized, controlled study. Cancer, 72: 1949.
Salminen,S., von Wright, A., Morelli, L., Marteau, P ., Brassart, D., de Vos, W. M. et al.,(1998) Demonstration of safety of pobioticsــــ a review. Int J Food Microbiol,44:93.
Seow, S, W., et al.(2002). Lactobacillus species is more cytotoxic to human bladder cancer cells than Mycobacterium Bovis.(Bacillus Calmette-Guerin).J of Urology, 168,2236-2239.
Sartor, R.B. (2005) Probiotic therapy of intestinal inflammation and infections.Curr OPin Gastroenterol 21, 44-50.
Takeuchi, K., Tomita, H., Fujimoto, S., Kudo, M., Kuwano, H. and Ike, Y. (2005) Drug resistance of Enterococcus faecium clinical isolates and the conjugative transfer of gentamicin and erythromycin resistance traits.FEMS Microbiol Lett 243,347-354.
Wang, c.Y., Mayo, M. W. and Baldwin, A. S., Jr. (1996). TNF-and Cancer therapy-induced apotosis: potentiation by inhibition of NF-0KappaB. Science, 274: 784.
Yasutake, N., Matsuzaki, T., Kimura, K. et al., (1999). The role of tumor necrosis factor (TNF)-α in the antitumor effect of intrapleural injection of Lactobacillus casei strain Shirota in mice. Med Microbiol Immunol (Berl), 188: 9.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2024 Hussien Abouelhag
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
